HomeCompareERFSF vs PFE

ERFSF vs PFE: Dividend Comparison 2026

ERFSF yields 0.95% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ERFSF wins by $3.76M in total portfolio value
10 years
ERFSF
ERFSF
● Live price
0.95%
Share price
$72.07
Annual div
$0.68
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3.81M
Annual income
$3,165,047.99
Full ERFSF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — ERFSF vs PFE

📍 ERFSF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodERFSFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ERFSF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ERFSF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ERFSF
Annual income on $10K today (after 15% tax)
$80.44/yr
After 10yr DRIP, annual income (after tax)
$2,690,290.79/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, ERFSF beats the other by $2,667,970.89/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ERFSF + PFE for your $10,000?

ERFSF: 50%PFE: 50%
100% PFE50/50100% ERFSF
Portfolio after 10yr
$1.93M
Annual income
$1,595,653.35/yr
Blended yield
82.74%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

ERFSF
Analyst Ratings
2
Buy
1
Hold
1
Sell
Consensus: Buy
Altman Z
3.1
Piotroski
5/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ERFSF buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricERFSFPFE
Forward yield0.95%6.13%
Annual dividend / share$0.68$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%13.2%
Portfolio after 10y$3.81M$49.6K
Annual income after 10y$3,165,047.99$26,258.71
Total dividends collected$3.73M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyHold

Year-by-year: ERFSF vs PFE ($10,000, DRIP)

YearERFSF PortfolioERFSF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$10,889$189.26$9,153$693.39+$1.7KERFSF
2$12,037$385.22$8,593$849.25+$3.4KERFSF
3$13,675$795.90$8,336$1,066.78+$5.3KERFSF
4$16,323$1,690.18$8,437$1,384.80+$7.9KERFSF
5$21,236$3,770.81$9,013$1,875.40+$12.2KERFSF
6$31,892$9,169.90$10,306$2,680.72+$21.6KERFSF
7$59,866$25,740.99$12,820$4,101.38+$47.0KERFSF
8$154,372$90,315.65$17,673$6,826.70+$136.7KERFSF
9$600,488$435,309.98$27,543$12,591.86+$572.9KERFSF
10$3,807,570$3,165,047.99$49,560$26,258.71+$3.76MERFSF

ERFSF vs PFE: Complete Analysis 2026

ERFSFStock

Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. The company offers a portfolio of approximately 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability, and purity of various products. It provides services such as agro-science, including biological assessment, consumer and human, and environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, such as product inspection, auditing, certification, training and consultation of food, consumer products, and healthcare and cosmetics; biopharma, and clinical diagnostics. In addition, the company offers consumer product testing, which include product compliance and audit, testing, certifications and approvals, inspections, training courses, and digital media and cyber security for various industries; cosmetics and personal care; environment testing, including water, air, soil, waste, and other products testing; and food and feed testing that include allergen, GMO, grain, meat, nano material, pesticides, and residual DNA testing. Further, it offers audit and certification, authenticity, carbohydrates, consulting, dioxins and POPs, food irradiation, labelling, law, heavy metals, identity preservation, mealtime, molecular and microbiology, mycotoxins, nutritional analyses, organic containments, packaging/migration, radioactivity, rapidest, sensorsy and consumer research, trainings, veterinary drug residues, and vitamins services. Additionally, the company provides forensic, genomic, maritime, materials and engineering, REACH, and technologies services. It operates approximately 900 laboratories in 54 countries. The company was founded in 1987 and is headquartered in Luxembourg City, Luxembourg.

Full ERFSF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this ERFSF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ERFSF vs SCHDERFSF vs JEPIERFSF vs OERFSF vs KOERFSF vs MAINERFSF vs JNJERFSF vs MRKERFSF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.